DTIL vs ZSQR
DTIL: Precision BioSciences is a clinical-stage biotechnology company leveraging its proprietary ARCUS gene editing platform to develop potentially curative in vivo therapies for genetic and infectious diseases. ZSQR: An early-stage biopharmaceutical company developing natural killer cell therapies and CAR platforms for cancer and infectious diseases, complemented by enterprise software capabilities.
Side-by-side fundamentals
| Metric | DTIL | ZSQR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $7.32 | $4.98 | |
| Market cap as of 2026-07-23 | $189M | $293M | |
| PEG as of 2026-07-23 | -0.02 | n/a | |
| Net margin as of 2026-07-23 | -96.7% | -832.3% | DTIL higher |
| Gross margin as of 2026-07-23 | n/a | +87.2% | |
| Operating margin as of 2026-07-23 | -86.8% | -901.2% | DTIL higher |
| ROE as of 2026-07-23 | -79.6% | -99.7% | DTIL higher |
| ROA as of 2026-07-23 | -34.8% | -75.5% | DTIL higher |
| Debt / equity as of 2026-07-23 | 0.29 | 0.01 | ZSQR lower |
| Revenue growth (YoY) as of 2026-07-23 | -11.9% | +2149.0% | ZSQR higher |
| Revenue CAGR (3y) SEC XBRL | +10.9% | n/a | |
| Beta as of 2026-07-23 | 1.27 | n/a | |
| 1-year return as of 2026-07-22 close | +50.6% | -67.2% | DTIL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.